Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

We report the clinical outcomes of 22 patients with primary intraocular lymphoma (PIOL) treated over a 15-year period. Patients with confirmed PIOL by central pathology review treated from 1994 to 2010 with isolated ocular (N=13) or central nervous system (CNS) plus ocular involvement (N=9) were included. Intraocular and CNS failure-free survival, relapse-free survival, and overall survival outcomes were analyzed. Median follow-up was 29.0 (range, 10.2 to 96.4) months. Sixteen patients (9 with isolated ocular, 7 with ocular and CNS disease) received combined modality therapy (CMT) consisting of systemic chemotherapy (usually high-dose methotrexate based) and orbital +/- whole-brain radiation. Two patients were treated with chemotherapy and 4 with local ocular therapy alone. Among patients with isolated ocular versus CNS involvement, CNS failure-free survival was 79% versus 57%, and intraocular failures were 62% versus 78% at 24 months. Median relapse-free survival was 34.0 versus 21.3 months (P=0.368), and overall survival 43.4 versus 30.3 months (P=0.744), respectively. Three patients treated with CMT (2 with isolated ocular and 1 with CNS involvement) with >1-year follow-up alive at the time of analysis never relapsed, and one remains disease-free >4.5 years after treatment. In this series of patients with PIOL+/- CNS disease, CNS and intraocular relapse were common. A trend toward better survival was seen among patients with isolated ocular presentation, and a limited number of long-term disease-free survivors seen after CMT.


Michelle M Kim, Bouthaina S Dabaja, Jeffrey Medeiros, Stella Kim, Pamela Allen, Patricia Chevez-Barrios, Dan S Gombos, Nathan Fowler. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. American journal of clinical oncology. 2016 Apr;39(2):109-13

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 24390272

View Full Text